Put up against placebo in the phase 3 EMBARK trial, delandistrogene moxeparvovec (Elevidys) did not significantly improve ...
The San Diego biotech made an unsolicited bid to buy Evotec for 2 billion euros. Elsewhere, Bluebird recorded its first ...
The U.S. Food and Drug Administration approved Kebilidi (eladocagene exuparvovec-tneq), an adeno-associated virus ...
Immunotherapy, which enhances the immune system's T cell response to eliminate cancer cells, has emerged as a key approach in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback